User:Goorgle/Books/Pharmacology Wiki 101

Pharmacology Wiki 101

 * 2,4-Dinitrophenol
 * 2-Arachidonoylglycerol
 * 4-Nitroquinoline 1-oxide
 * 5-HT2c receptor agonist
 * 5-HT2C receptor agonists
 * Acemannan
 * Active ingredient
 * Active metabolite
 * Addiction medicine
 * Adipotide
 * Adrenergic
 * Adrenorphin
 * Adverse drug reaction
 * Adverse effect
 * Agonist
 * Agonist–antagonist
 * Alcohol withdrawal syndrome
 * Allosteric modulator
 * Amfecloral
 * Amidorphin
 * Amino acid neurotransmitter
 * Anabolic steroid
 * Anandamide
 * Anatomical Therapeutic Chemical Classification System
 * Anavex Life Sciences
 * Anesthetic
 * Anorectic
 * Antacid
 * Anti-inflammatory
 * Anti-obesity medication
 * Anticoagulant
 * Antidepressant
 * Antimicrobial pharmacodynamics
 * Antimigraine
 * Antimony pill
 * Antisialagogue
 * Antitarget
 * Antithyroid agent
 * Applicability domain
 * Aspartic acid
 * Association for Ocular Pharmacology and Therapeutics
 * Asuragen
 * Augmentation (psychiatry)
 * Australian Medicines Handbook
 * Australian Pharmaceutical Formulary
 * Autopharmacology
 * Azalanstat
 * Baseline (pharmacology)
 * Beloranib
 * Benfluorex
 * Benzodiazepine
 * Benzodiazepine dependence
 * Benzodiazepine withdrawal syndrome
 * Benzphetamine
 * Bernice Eddy
 * Beta-endorphin
 * Binding coefficient
 * Binding selectivity
 * Bioassay
 * Biologic medical product
 * Biological activity
 * Biological target
 * Biopharmaceutics Classification System
 * Biopharmacology
 * Biotechnology in pharmaceutical manufacturing
 * Black triangle (pharmacovigilance)
 * Blind experiment
 * Blood/gas partition coefficient
 * Body surface area
 * Bolus (medicine)
 * British Approved Name
 * British National Formulary for Children
 * British Pharmaceutical Codex
 * British Pharmacopoeia
 * Bupropion/naltrexone
 * Bupropion/zonisamide
 * Burow's solution
 * Cancer Trials Support Unit
 * Catecholamine
 * Ceiling effect (pharmacology)
 * Central Drugs Standard Control Organization
 * Certain safety factor
 * Cetilistat
 * Channel blocker
 * Channel opener
 * Chemogenomics
 * Chemotactic drug-targeting
 * Chemotherapy-induced acral erythema
 * Chinese Medical Herbology and Pharmacology
 * Cholinergic crisis
 * Christophe Wiart
 * Clark's rule
 * Classical pharmacology
 * Classification of Pharmaco-Therapeutic Referrals
 * Clearance (medicine)
 * Clinical investigator
 * Clinical neurochemistry
 * Clinical pharmacology
 * Clinical trial
 * Clinical trials unit
 * Combination drug
 * Combination therapy
 * Combined drug intoxication
 * Compendium of Materia Medica
 * Competitive antagonist
 * Compliance (medicine)
 * Compound spirit of ether
 * Compounding
 * Concord Prison Experiment
 * Conditioned place preference
 * Context-sensitive half-life
 * Cooperstown cocktail
 * Corticosteroid
 * Cosmetic pharmacology
 * COSTART
 * Counterirritant
 * Course (medicine)
 * Cross-tolerance
 * Crossover study
 * Cytel
 * Cytoprotection
 * Delayed release
 * Deliriant
 * Dermal patch
 * Desensitization (medicine)
 * Desmoteplase
 * Detoxication
 * Dexfenfluramine
 * Dilution assay
 * Dirlotapide
 * Discovery and development of mTOR inhibitors
 * Discovery and development of thalidomide and its analogs
 * Dissociative
 * Distribution (pharmacology)
 * Dixanthogen
 * Dopamine
 * Dopaminergic
 * Dosage form
 * Dose (biochemistry)
 * Dose concentration
 * Dose–response relationship
 * Dosing
 * Drug action
 * Drug coupon
 * Drug design
 * Drug development
 * Drug discovery
 * Drug eruption
 * Drug holiday
 * Drug Identification Number
 * Drug interaction
 * Drug intolerance
 * Drug metabolism
 * Drug nomenclature
 * Drug reaction testing
 * Drug repositioning
 * Drug resistance
 * Drug tolerance
 * Druglikeness
 * Drugs in pregnancy
 * Dynorphin
 * Eagle effect
 * EC50
 * Effective dose (pharmacology)
 * Effective half-life
 * Effects of long-term benzodiazepine use
 * Effervescent tablet
 * Eledoisin
 * Elimination (pharmacology)
 * Empathogen-entactogen
 * Endogenous agonist
 * Endorphins
 * Endozepine
 * Enteric coating
 * Environmental impact of pharmaceuticals and personal care products
 * Epinephrine
 * EPPTB
 * Epratuzumab
 * Equianalgesic
 * Equipotent molar ratio
 * Ethnopsychopharmacology
 * Eudysmic ratio
 * Euphoriant
 * European Pharmacopoeia
 * Excipient
 * Expanded access
 * Experimental drug
 * False neurotransmitter
 * Farmacotherapeutisch Kompas
 * Federation of European Pharmacological Societies
 * Fenbutrazate
 * FIASMA
 * Fine chemical
 * First-dose phenomenon
 * FMRFamide
 * Food and Drug Administration
 * Forced diuresis
 * Formulary (pharmacy)
 * Formulation
 * Functional selectivity
 * GABA antagonist
 * GABAA receptor positive allosteric modulators
 * Galactagogue
 * Gamma-Aminobutyric acid
 * Gamma-Hydroxybutyric acid
 * Gasotransmitter
 * Gastrin-releasing peptide
 * General anaesthetic
 * Generic Product Identifier
 * Gerald Muench
 * Gliotransmitter
 * Glucuronide
 * Glutamate carboxypeptidase II
 * Glutamate receptor
 * Glutamic acid
 * Glycerite
 * Glycine
 * Goodman & Gilman's The Pharmacological Basis of Therapeutics
 * Grapefruit–drug interactions
 * GS-39783
 * Gu (poison)
 * Guide to Pharmacology
 * Hazardous drugs
 * HERG
 * Heteromer
 * Histamine
 * History of catecholamine research
 * History of pharmacy
 * Hit to lead
 * HIV drug resistance
 * Hormonal therapy (oncology)
 * HTR3A
 * HTR3B
 * HTR3C
 * HTR3D
 * HTR3E
 * Hy's law
 * HYDIA
 * Hypnotic
 * IC50
 * Idiosyncratic drug reaction
 * IdMOC
 * Indian Pharmacopoeia Commission
 * Indirect agonist
 * Indolamines
 * Influenza Antiviral Drug Search
 * Injection (medicine)
 * Institutional review board
 * Interaction
 * International Cannabinoid Research Society
 * International Nonproprietary Name
 * International Psychopharmacology Algorithm Project
 * International unit
 * Intrinsic activity
 * Inverse agonist
 * Ion trapping
 * IUPHAR Database
 * Japanese Approved Name
 * Japanese Pharmacopoeia
 * Kindling (sedative-hypnotic withdrawal)
 * King's American Dispensatory
 * Krzysztof Palczewski
 * Laxative
 * Lemont Kier
 * Leukemia inhibitory factor
 * Li Shizhen
 * Liberation (pharmacology)
 * Lipinski's rule of five
 * Lipophilic efficiency
 * List of drug interactions
 * List of pharmaceutical compound number prefixes
 * Loading dose
 * Local anesthetic
 * Loewe additivity
 * Maintenance dose
 * Malotilate
 * Martindale: The Complete Drug Reference
 * Materia medica
 * Mayamycin
 * Mechanism of action
 * MedDRA
 * Median toxic dose
 * Medical prescription
 * Medicina Plinii
 * Medicinal product
 * Medicine
 * Melafix
 * MGS-0039
 * Microdispensing
 * Miodrag Radulovacki
 * Monastrol
 * Monoamine neurotransmitter
 * Monotherapy
 * Most probable number
 * Multidrug-resistant gram-negative bacteria
 * Multiple drug resistance
 * Murphy drip
 * Muscle relaxant
 * N-Methyl-D-aspartic acid
 * Named patient programs
 * NAMI-A
 * Nasal spray
 * National Agency for Food and Drug Administration and Control
 * National Drug Code
 * National Drug Code System
 * National Medicinal Drugs Policy
 * National Pharmaceutical Product Index
 * National pharmaceuticals policy
 * Neoendorphin
 * Neural drug delivery systems
 * Neuropharmacology
 * Neuropharmacology (journal)
 * Neuropsychopharmacology
 * Neurotoxin
 * Neurotransmitter
 * Nitric oxide
 * Nocebo
 * Non-competitive inhibition
 * Non-noradrenergic, non-cholinergic transmitter
 * Norepinephrine
 * Norfenefrine
 * Number needed to harm
 * Number needed to treat
 * Ocriplasmin
 * Oculomucocutaneous syndrome
 * Off-label use
 * Officinal
 * Oleoylethanolamide
 * Olesoxime
 * Onset of action
 * Open channel block
 * Open-label trial
 * Optimal biological dose
 * Oral administration
 * Oral sedation dentistry
 * Oralin (insulin)
 * Osmotic diuretic
 * OSU-6162
 * Oxygen diffusion-enhancing compound
 * Oxytocin
 * Oxytrex
 * Paradoxical disinhibition
 * Paradoxical reaction
 * Partial agonist
 * PDE5 drug design
 * Penicillin drug reaction
 * Personalized medicine
 * Peter Rheinstein
 * Pharma fraud
 * Pharmaceutic adjuvant
 * Pharmaceutical code
 * Pharmaceutical drug
 * Pharmaceutical glaze
 * Pharmaceutical industry
 * Pharmaceutical ink
 * Pharmaceutical medicine
 * Pharmaceutical Press
 * Pharmaceutical sciences
 * Pharmacodynamics
 * Pharmacoeconomics
 * Pharmacoepidemiology
 * Pharmacogenetics
 * Pharmacogenomics
 * Pharmacognosy
 * Pharmacoinformatics
 * Pharmacokinetics
 * Pharmacological Calvinism
 * Pharmacological chaperone
 * Pharmacological gene therapy
 * Pharmacology
 * Pharmacometrics
 * Pharmacon
 * Pharmaconomist
 * Pharmaconomy
 * Pharmacophore discovery
 * Pharmacopoeia
 * Pharmacopoeia of the People's Republic of China
 * Pharmacotherapy
 * Pharmacotoxicology
 * Pharmacovigilance
 * Pharmacy
 * Pharming (genetics)
 * Phasic transmitter
 * Phonophoresis
 * Phospholipidosis
 * Photosensitivity
 * Physiological agonism and antagonism
 * Physiologically based pharmacokinetic modelling
 * Phytopharmacology
 * Pill dispenser
 * Pill organizer
 * PK/PD models
 * Placebo
 * Placebo-controlled study
 * Plateau principle
 * Pleiotropy (drugs)
 * Polymersome
 * Polypharmacy
 * Polysubstance dependence
 * Porous silicon
 * Positional alcohol nystagmus
 * Postmarketing surveillance
 * Potency (pharmacology)
 * PPAR agonist
 * Pregnancy category
 * Prescription cascade
 * Prescription costs
 * Prescription drug
 * Prescriptive authority for psychologists movement
 * Proctosedyl
 * Prodrug
 * Prodynorphin
 * Professional Further Education in Clinical Pharmacy and Public Health
 * Prostaglandin analogue
 * Protective index
 * Provocation test
 * Psychiatric medication
 * Psychopharmacology
 * Psychotomimetic
 * PTC Therapeutics
 * Qualified Person for Pharmacovigilance
 * Quantitative pharmacology
 * Quantitative structure–activity relationship
 * Rate of infusion
 * Rebound effect
 * Receptor antagonist
 * Releasing agent
 * Research chemical
 * Research on Adverse Drug Events and Reports
 * Retrometabolic drug design
 * Reuptake
 * Reuptake inhibitor
 * Reverse pharmacology
 * Reward dependence
 * Ritalin class action lawsuits
 * Robertson Centre for Biostatistics
 * Route of administration
 * Safety pharmacology
 * Schild regression
 * Sedative
 * Selective receptor modulator
 * Sepiapterin reductase deficiency
 * Serotonergic
 * Serotonin
 * Serotonin pathways
 * Serotonin syndrome
 * Side effect
 * Sodium ferric gluconate complex
 * Source document
 * Specol
 * Statisticians in the Pharmaceutical Industry
 * Stearoylethanolamide
 * Structured intermittent therapy
 * Subcutaneous injection
 * Substance P
 * Summary of Product Characteristics
 * Suspected Adverse Reaction Surveillance Scheme
 * Syed Ziaur Rahman
 * Synaptic pharmacology
 * Systems pharmacology
 * TA-CD
 * TA-NIC
 * Table of volume of distribution for drugs
 * Tablet (pharmacy)
 * Tablet hardness testing
 * Tachykinin peptides
 * Tachyphylaxis
 * Tasquinimod
 * Tetrachlorodecaoxide
 * The International Pharmacopoeia
 * The Pharma Letter
 * Therapeutic effect
 * Therapeutic index
 * Therapeutic Targets Database
 * Therapeutic window
 * Therapy
 * Thyroid hormone
 * Time release technology
 * Timeline of antibiotics
 * Toba medicine container
 * Tolerability
 * Toxication
 * Toxicodynamics
 * Trace amine
 * Transdermal patch
 * Trough level
 * Ukrainian Pharmacy Holding
 * Uncoupling (neuropsychopharmacology)
 * Unique Ingredient Identifier
 * United States Adopted Name
 * United States Pharmacopeia
 * Uppsala Monitoring Centre
 * USP Dissolution Apparatus 2
 * Vasopressin analogue
 * Volume of distribution
 * WHO Drug Dictionary
 * WHOART
 * William E. Evans (pharmacist)
 * Zoopharmacognosy